Scholars Central

EditorialPublished 24 Jun 2012

Pulmonary Venous Hypertension- An On Going Quest for Treatment: Is PDE5 Inhibition the Right Solution?

Authors: Lavanya Bellumkonda

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Pulmonary venous hypertension is pulmonary hypertension resulting from elevated left sided filling pressures. This may result from chronic elevation of left atrial pressures from heart failure; either heart failure with reduced ejection fraction (HFrEF) or heart failure with preserved ejection fraction (HFpEF) or from valvular heart disease. This is classified as Group 2 pulmonary hypertension in the Dana point classification. Pulmonary hypertension due to left heart disease is defined as mean pulmonary arterial pressure (mPAP) greater than or equal to 25 mm Hg, pulmonary capillary wedge pressure (PCWP) of greater than or equal to 15 mm Hg and pulmonary vascular resistance (PVR) greater than 3WU.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Cardiovascular Research
  • SubjectCardiology
  • BylineArticles whose byline prints “Lavanya Bellumkonda”